Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer

NCT07108127 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer
HER2-positive

Interventions

DRUG: Trastuzumab biosimilars and pertuzumab biosimilars plus XELOX

Sponsor

Peking Union Medical College Hospital